PMID- 33016503
OWN - NLM
STAT- Publisher
LR  - 20240222
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2020 Oct 5
TI  - Efficacy and safety of DPP-IV inhibitors combined with basal insulin in the 
      treatment of type 2 diabetes.
LID - 10.1111/1753-0407.13119 [doi]
AB  - BACKGROUND: To evaluate the efficacy and safety of dipeptidyl peptidase IV 
      (DPP-IV) inhibitors when added to insulin therapy in patients with type 2 
      diabetes mellitus (T2DM). METHODS: PubMed, EMBASE, the Web of Science, and the 
      Cochrane Library were systematically searched for randomized controlled trials 
      (RCTs) exploring the efficacy or safety of DPP-IV inhibitors in T2DM patients. 
      The quality of the included RCTs was assessed with the Cochrane risk-of-bias 
      tool. For outcomes, odds ratios or weighted mean differences (WMDs) with 95% CIs 
      were calculated using both random- and fixed-effects models. RESULTS: A total of 
      16 studies were included in the meta-analysis with 5418 participants. 
      Glycosylated hemoglobin (HbA1c) was significantly decreased in the DPP-IV 
      inhibitors with insulin (DPP-IVi/INS) group compared with the insulin-alone (with 
      or without placebo) group (WMD = -0.62%; 95% CI: -0.74, -0.49; P < .05). 
      Consistent with this finding, the fasting blood glucose (FBG)-lowering effect 
      (WMD = -0.61 mmol/L; 95% CI: -0.77, -0.45; P < .05) and 2-hour postprandial 
      glucose (2hPPG)-lowering efficacy (WMD = -2.39 mmol/L; 95% CI: -2.81, -1.97; 
      P < .05) in the DPP-IVi/INS group were also significantly better than in the 
      insulin-alone group. Regarding safety indicators, compared with the insulin-alone 
      group, DPP-IVi/INS treatments had no association with the risk of adverse 
      effects, including hypoglycemia, adverse events (AEs), and serious adverse events 
      (SAEs). CONCLUSIONS: Compared with insulin treatment alone, treatment with 
      DPP-IVi/INS improved HbA1c, FBG, and 2hPPG without increasing the risk of 
      hypoglycemia, AEs, or SAEs.
CI  - (c) 2020 Ruijin Hospital, Shanghai JiaoTong University School of Medicine and John 
      Wiley & Sons Australia, Ltd.
FAU - Pan, Zhenhong
AU  - Pan Z
FAU - Yang, Yan
AU  - Yang Y
AD  - Department of Metabolism and Endocrinology, National Clinical Research Center for 
      Metabolic Diseases, Metabolic Syndrome Research Center, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, The Second 
      Xiangya Hospital of Central South University, Changsha, China.
FAU - Zhang, Jingjing
AU  - Zhang J
AUID- ORCID: 0000-0002-9155-8979
AD  - Department of Metabolism and Endocrinology, National Clinical Research Center for 
      Metabolic Diseases, Metabolic Syndrome Research Center, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, The Second 
      Xiangya Hospital of Central South University, Changsha, China.
LA  - eng
GR  - Natural Science Foundation of China, the Planned Science and Technology Project 
      of Hunan Province and National key research and development program./
PT  - Journal Article
DEP - 20201005
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
SB  - IM
OTO - NOTNLM
OT  - DPP-IV inhibitor
OT  - T2DM
OT  - insulin
OT  - meta-analysis
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/10/05 08:43
PHST- 2020/05/29 00:00 [received]
PHST- 2020/08/29 00:00 [revised]
PHST- 2020/09/26 00:00 [accepted]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
PHST- 2020/10/05 08:43 [entrez]
AID - 10.1111/1753-0407.13119 [doi]
PST - aheadofprint
SO  - J Diabetes. 2020 Oct 5. doi: 10.1111/1753-0407.13119.